Rezolute, Inc. (RZLT)
NASDAQ: RZLT · Real-Time Price · USD
9.57
-0.03 (-0.31%)
Nov 7, 2025, 10:57 AM EST - Market open
Rezolute Employees
Rezolute had 71 employees as of June 30, 2025. The number of employees increased by 12 or 20.34% compared to the previous year.
Employees
71
Change (1Y)
12
Growth (1Y)
20.34%
Revenue / Employee
n/a
Profits / Employee
-$1,087,099
Market Cap
869.22M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 71 | 12 | 20.34% |
| Jun 30, 2024 | 59 | 8 | 15.69% |
| Jun 30, 2023 | 51 | 9 | 21.43% |
| Jun 30, 2022 | 42 | 16 | 61.54% |
| Jun 30, 2021 | 26 | 3 | 13.04% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RZLT News
- 18 hours ago - Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 2 days ago - Rezolute to Host Virtual Investor Event on Ersodetug Development Program - GlobeNewsWire
- 23 days ago - Rezolute to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Rezolute: FDA Pivotal Trial Alignment Change Further Bolsters Ersodetug - Seeking Alpha
- 2 months ago - Rezolute, Inc. (RZLT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism - GlobeNewsWire